Company intelligence / Profile preview

Aperiam Bio

Austin, Texas, United Statesaperiambio.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Aperiam Bio has demonstrated the ability to engineer hyperfolding protein variants with significantly improved expression, solubility, and activity. Their technology has been validated in technical reagents and cosmetic enzymes. For pulmonary biologic applications, they report retaining over two-thirds of protein activity after harsh treatments like nebulization. No human clinical trial results have been published yet.

Therapeutic areas: OtherPulmonology
Modalities: Engineered proteins (hyperfolding variants)Enzymes (stabilized and solubilized)Pulmonary biologics
Industry: Biotech

Partnerships

Companies developing technical reagents and pulmonary products are mentioned as partners but not named specifically.

Beyond the preview

Go deeper on Aperiam Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aperiam Bio.

Explore the full profile